5 October 2015 - Alkermes today announced that the U.S. Food and Drug Administration (FDA) has approved Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection. Alkermes is preparing to launch Aristata immediately.

“Aristada is a new treatment option designed to offer flexibility to meet the real-world needs of patients suffering from schizophrenia and the healthcare professionals providing their care,” said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. “Building on nearly two decades of experience developing innovative medicines for chronic and serious CNS diseases, we are dedicated to helping to improve the lives of patients as well as meeting the needs within the treatment ecosystem of caregivers, physicians, payers and society. We look forward to making Aristada available to patients and healthcare providers as quickly as possible.”

For more details, go to: http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=RssLanding&cat=news&id=2094291